Tilray Brands (NASDAQ:TLRY) shares rise, driven by growth in beverages and distribution
Shares of Tilray Brands, Inc. climbed 6.4% to $4.47 at the start of trading on Friday. The company’s stock built on Thursday’s 5.3% gain.
Tilray Brands (TLRY) stock jumps in premarket after record $218 mln quarter and net cash turn
Tilray Brands, Inc. shares rose nearly 9% in premarket trading on Friday after the cannabis and craft beer maker reported quarterly results after the bell. The stock was last up 8.98% at $9.95 after ending Thursday at $9.13.
Tilray Brands (TLRY) Stock News Today: Cannabis Rescheduling, Earnings Date, Reverse Split, and Analyst Forecasts (Dec. 24, 2025)
Tilray Brands, Inc. has spent December doing what cannabis stocks do best: moving fast, arguing loudly with gravity, and reacting to headlines like they’re caffeine. As of Wednesday, December 24, 2025, TLRY is trading around $10.53.
Tilray Brands (TLRY) Stock News Today: Trump Cannabis Rescheduling Reports Fuel Volatility, Fresh Forecasts and Key Levels (Dec. 17, 2025)
Tilray Brands, Inc. stock is back in the spotlight on December 17, 2025, as cannabis stocks react—again—to fast-moving headlines around potential U.S. federal marijuana rescheduling. In the latest session, TLRY traded around $13.94, up roughly 27% on the day, after swinging between about $10.32 and $14.54—a reminder that Tilray remains one of the market’s most headline-sensitive, momentum-driven names.
Tilray Brands (TLRY) Stock News Today: Cannabis Rally Cools as Trump Schedule III Speculation Fuels Volatility
Tilray Brands, Inc. is back in the spotlight on December 15 after one of its biggest momentum bursts in years—followed by an equally fast reality check. The stock’s latest swing is being driven less by quarterly fundamentals and more by a single macro catalyst: growing expectations that President Donald Trump could move to ease federal marijuana restrictions by pushing a reclassification of cannabis to Schedule III.
Tilray Stock Surges as Trump Schedule III Buzz Collides With New Vape Launch and Reverse Split Fallout
Tilray Brands is back at the center of the cannabis market’s biggest catalyst in years: growing expectations that President Donald Trump could move to ease federal marijuana restrictions by pushing a reclassification of cannabis to Schedule III. On Monday, December 15, 2025, the optimism spilled into global trading, with cannabis names extending last week’s explosive rally as investors tried to price what a Schedule III world could mean for taxes, banking access, and institutional participation. Reuters+1
Tilray Brands (TLRY) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025
Tilray Brands, Inc. is back in the spotlight heading into Monday’s U.S. market open after a policy-driven surge that reminded investors why cannabis-linked equities can move fast—often on headlines more than fundamentals.
Tilray Brands (TLRY) Stock Jumps on Marijuana Rescheduling Buzz: This Week’s Move, Latest News, and Week-Ahead Outlook (Updated Dec. 12, 2025)
Updated: Friday, Dec. 12, 2025Meta description: Tilray surged this week as cannabis stocks spiked on reports Trump may push marijuana rescheduling. Here’s what happened and what to watch next week.
Top Stock Gainers Today (Dec. 12, 2025, 12:30 p.m. ET): cbdMD, Canopy Growth, Tilray Lead a Cannabis-Fueled Rally
Here are the biggest US stock market gainers at midday on Dec. 12, 2025—plus what’s driving the moves, from cannabis policy headlines to earnings reports and SEC filings. StockAnalysis+2Reuters+2
Tilray Brands (TLRY) Stock Jumps on Trump Marijuana Rescheduling Report: Latest News, Forecasts, and Analyst Views (Dec. 12, 2025)
Meta description: Tilray Brands is surging as cannabis stocks rally on fresh U.S. rescheduling headlines. Here’s what’s driving TLRY, what analysts forecast, and what to watch next.
US Stock Market Premarket Top Gainers Today (Dec. 12, 2025): Lululemon Surges, Cannabis Stocks Rally, Mitek and Quanex Jump
SEO summary: Here are the biggest US stock market premarket gainers today and the news driving them, including Lululemon’s earnings and CEO transition, a cannabis-stock surge tied to marijuana rescheduling headlines, and earnings-driven jumps in Mitek and Quanex. Nasdaq+4StockAnalysis+4Reuters+4
Tilray Brands (TLRY) Soars After Reverse Stock Split and Cannabis Bill Hopes: Stock Forecast, Price Targets and 2026 Outlook
Tilray Brands, Inc. just reminded investors how violently cannabis stocks can move.
Tilray Brands (TLRY) Stock in December 2025: Reverse Split, 90% Rally and What the Latest Forecasts Really Say
Data and commentary up to 7 December 2025, with a focus on developments and analysis published since 6 December 2025. This article is for information only and is not investment advice.
Tilray Stock Today, November 23, 2025: TLRY Under $1 as AI Trading Signals, Hemp Rules and Big Holders Collide
Tilray Brands stock is back in the spotlight this Sunday, November 23, 2025, for all the reasons that make cannabis names both fascinating and stressful to follow:the share price has slipped back under $1, new AI-driven trading plans dropped this morning, a fresh “millionaire maker” think-piece is circulating, and regulators are pulling the sector in opposite directions.
Tilray Brands (TLRY) on November 23, 2025: Stock Under $1, Fresh AI Trading Signals, and a Tug-of-War Between Fundamentals and Regulation
Tilray Brands, Inc. is back in focus today as new AI-driven trading signals, updated valuation models, and recent analyst forecasts collide with a volatile share price that’s again trading under $1.
Tilray’s 300% Rally and Surprise Profit: Is the Cannabis Comeback Real?
Tilray Brands kicked off its fiscal 2026 with better-than-expected results, signaling that aggressive cost-cutting and diversification efforts are bearing fruit. The company’s Q1 FY2026 revenue hit $209.5 million, a 5% increase over last year’s quarter stocktitan.net. More impressively, Tilray managed to swing to a net profit of $1.5 million – a stark improvement from the -$34.7 million loss in the prior-year period stocktitan.net stocktitan.net. This marks one of Tilray’s first profitable quarters since its 2018 IPO, a milestone achieved through tighter operational discipline. Adjusted EBITDA came in at $10.2 million, indicating improving core profitability stocktitan.net.
Tilray Stock Skyrockets 300% on Cannabis Reform Hopes – Is TLRY’s Rally Sustainable?
Tilray’s stock has been on a tear in recent months, staging a stunning turnaround from penny-stock levels. The share price has quadrupled since early July – rising from well under $0.5 to around $1.7 by early October Nasdaq. Year-to-date, TLRY is up ~22% after being down over 20% mid-year Talkmarkets Hi Plainscoop. This rebound has rescued Tilray from the brink of a Nasdaq delisting – the company had even sought a compliance extension when its shares languished below $1 in the summer Hi Plainscoop.
Tilray Stock Skyrockets 300% on Cannabis Reform Hopes – Will TLRY’s Rally Last?
Tilray’s stock has been on a wild ride in early October 2025, propelled by a flurry of cannabis policy news. In the first week of October, TLRY jumped over 8% in one day after an apparent breakthrough in U.S. marijuana reform sentimentnasdaq.comnasdaq.com. The trigger: several prominent Republican senators voiced unexpected support for easing federal cannabis laws, and former President Donald Trump – now in his second term – signaled openness to rescheduling marijuana. MarijuanaMoment reports that in late September, Trump shared a video touting CBD’s health benefits for seniors, and GOP Senators Lisa Murkowski said moving cannabis to Schedule III “is totally a game changer” while Kevin Cramer confirmed Trump “has said it… if he reschedules, that is a big deal”marijuanamoment.netmarijuanamoment.net. Such rhetoric from traditionally resistant lawmakers shocked the market and “seemed to take a little step forward” the slow march toward U.S. marijuana legalizationnasdaq.com. Cannabis stocks across the board rallied on the news, with Tilray notable as one of the biggest gainers, climbing over 8% that daynasdaq.com.
TechStock² Updates
